The Valley Desk

ArticleJournal of the American Academy of DermatologyPublished

Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Journal of the American Academy of Dermatology
Published
Subject terms
Humans; Skin Neoplasms; Psoriasis; Dermatologic Agents; Treatment Outcome; Severity of Illness Index; Follow-Up Studies; Double-Blind Method; Uterine Cervical Neoplasms; Female; Antibodies, Monoclonal, Humanized; Adalimumab
PubMed ID
37019386
Added to directory
Source checked

Report a correction or request removal